BioMerieux benefits from the “Covid effect” on tests

Posted on Sep 1, 2021 at 4:46 PMUpdated on Sep 1, 2021, 5:26 PM

BioMérieux is on the rise, and not just because of Covid 19, which has led to a surge in demand for tests. As of June 30, 2021, the company specializing in in vitro diagnostics saw its half-year sales reach 1.57 billion euros, thus posting organic growth of 12.3%, reduced to 6.6% due to unfavorable currency effects.

Thanks to this growth dynamic, the group has seen its profitability improve. As a result, current operating income increased by 48% to € 374 million (despite € 29 million of unfavorable currency impacts), or a current operating margin of 23.8%. The gross margin, it reached 915 million, or 58.1% of turnover (against 55.3% a year earlier). Finally, EBITDA is 471 million euros, or 29.2% of turnover, up 37% compared to the same period of 2020.

Leave a Reply

Your email address will not be published. Required fields are marked *